Rigel Pharmaceuticals, Inc. (RIGL): Price and Financial Metrics

Rigel Pharmaceuticals, Inc. (RIGL): $1.20

0.03 (-2.44%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add RIGL to Watchlist
Sign Up

RIGL Price/Volume Stats

Current price $1.20 52-week high $1.96
Prev. close $1.23 52-week low $0.71
Day low $1.18 Volume 3,746,700
Day high $1.24 Avg. volume 1,266,816
50-day MA $1.34 Dividend yield N/A
200-day MA $1.20 Market Cap 210.49M

RIGL Stock Price Chart Interactive Chart >


Rigel Pharmaceuticals, Inc. (RIGL) Company Bio


Rigel Pharmaceuticals, Inc. engages in the discovery and development of small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders. The company was founded in 1996 and is based in South San Francisco, California.


RIGL Latest News Stream


Event/Time News Detail
Loading, please wait...

RIGL Latest Social Stream


Loading social stream, please wait...

View Full RIGL Social Stream

Latest RIGL News From Around the Web

Below are the latest news stories about RIGEL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RIGL as an investment opportunity.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Stock Catapults 44% Though Its Price And Business Still Lag The Industry

Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shareholders would be excited to see that the share price has had a great...

Yahoo | December 18, 2023

Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders are up 20% this past week, but still in the red over the last three years

This month, we saw the Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) up an impressive 56%. But that is small recompense...

Yahoo | December 12, 2023

Best Momentum Stock to Buy for December 8th

BRSP and RIGL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 8, 2023.

Yahoo | December 8, 2023

Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a multi-year strategic development collaboration to expand the evaluation of REZLIDHIA® (olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers.

Yahoo | December 8, 2023

Best Momentum Stocks to Buy for November 22nd

BWAY, RIGL and BROS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 22, 2023.

Yahoo | November 22, 2023

Read More 'RIGL' Stories Here

RIGL Price Returns

1-mo -11.76%
3-mo -11.76%
6-mo 26.41%
1-year -2.44%
3-year -66.48%
5-year -48.28%
YTD -17.24%
2023 -3.33%
2022 -43.40%
2021 -24.29%
2020 63.55%
2019 -6.96%

Continue Researching RIGL

Here are a few links from around the web to help you further your research on Rigel Pharmaceuticals Inc's stock as an investment opportunity:

Rigel Pharmaceuticals Inc (RIGL) Stock Price | Nasdaq
Rigel Pharmaceuticals Inc (RIGL) Stock Quote, History and News - Yahoo Finance
Rigel Pharmaceuticals Inc (RIGL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!